AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00816881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flutter mucus clearance device
Description: five minutes every session, four sessions per day
Study NCT03084926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0274
Description: Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons
Study NCT01394900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CNU Intervention
Description: Notions that strengthen the closeness with one's partner, connect with similar couples, and visibly strengthen a community as key to combating dynamics that cause poor communication, isolation, fragmentation of the Black MSM community.
Study NCT01394900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WP Intervention
Description: Attention control condition - WP focuses on nutrition, fitness, healthcare, and stress management. Given the prevalence of health problems among the target population, WP emphasizes adherence to medical guidance and medication regimens.
Study NCT01760096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole+cyclosporin A+Glucocorticoids
Description: Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)
Study NCT01760096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporin A+Glucocorticoids
Description: cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)
Study NCT01760096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Glucocorticoids0.25mg/kg every day(prednisone)
Study NCT03406728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PDSAFEX
Description: PDSAFEX is a week by week, progressive, exercise protocol that is followed. It lasts 12 weeks.
Study NCT03406728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: Participants will be asked to maintain their day to day life as consistently as possible for the 12 week duration of the study.
Study NCT03406728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIRTUAL REALITY
Description: WorldViz Oculus Rift Move package (headset and software).
Study NCT02618616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL-3893787
Study NCT02618616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03861910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: hypoallergenic formulas
Description: hypoallergenic formulas used for cow milk allergy treatment
Study NCT04807465 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: G-Premio Bond in etch&rinse mode
Description: The phosphoric acid gel was applied to enamel and dentin washed for 5s and was dried gently with air spray. The adhesive system was applied to enamel and dentin surfaces and leave it in place for 10s.
Study NCT04807465 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: G-Premio Bond in selective-etch mode
Description: The phosphoric acid was applied only on enamel for 10-15s then washed and was gently dried with air spray. The adhesive system was applied to enamel and dentin surfaces.
Study NCT04807465 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: G-Premio Bond in self-etch mode
Description: The adhesive system was applied to the enamel and dentin surfaces.
Study NCT00936442 — intervention group
Intervention type: DRUG
Intervention: Anastrozole
Description: (Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
Study NCT00936442 — intervention group
Intervention type: OTHER
Intervention: Educational materials
Description: Reception of educational material on regular basis.
Study NCT02062047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days
Study NCT02062047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PMSRP
Description: Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
Study NCT01265355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-rotavirus protein
Description: 11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
Study NCT01265355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin 1 gm daily
Study NCT04697277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section
Study NCT03634124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Additional blood test of 4,5 ml of venous blood
Study NCT03634124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Vascular ultrasonic vascular exploration of the lower limbs
Study NCT04451122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cleansing the eyelid margins
Description: using eyelid cleaning wipes to cleansing the eyelid margins
Study NCT04503525 — intervention group
Intervention type: OTHER
Intervention: Nutritional assessment
Description: Nutritional assessment in COVID patients
Study NCT01353222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DN24-02
Description: DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.
Study NCT01353222 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Observation only until documentation of disease recurrence.
Study NCT04794231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressing
Description: a standard breathable, hypoallergenic, transparent dressing (TegadermTM 1635 \[8.5 x 10.5cm\] or 1633 \[7 × 8.5 cm\] depending on patient size; 3M, Neuss, Germany)
Study NCT04794231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate -impregnated dressing group
Description: A chlorhexidine gluconate -gel impregnated transparent dressing (TegadermTM CHG 1660R \[7 x 8.5 cm\] or \[11.5 x 8.5 cm\] depending on patient size; 3M, Neuss, Germany).
Study NCT02062047 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application and irrigation of placebo, rinsing placebo solution during 60 days
Study NCT00653458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ODT, 8 mg, single-dose, fed conditions
Study NCT00653458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: ODT, 8 mg, single-dose, under fed conditions
Study NCT00542880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
Study NCT00542880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide Diskus (salmeterol/fluticasone) 50/500 μg
Study NCT01269879 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexi-Bar vibration device only
Description: daily vibration training 10min twice
Study NCT01269879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexi-Bar + XCO-Trainer
Description: XCO-Trainer is a way to overload the cardiovascular system and the core muscles during running. An oscillating mass inside the XCO-Trainer is activated when the XCO is propelled forward and backward with force. The movement of the mass triggers a series of responses from the runners' body.~In addition Flexi-Bar vibration training as in the referred active comparator group
Study NCT00696384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and \<130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.~Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit.
Study NCT00696384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
Description: Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
Study NCT00696384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
Study NCT01547897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NOX-E36
Description: 0.5 mg/kg study drug or placebo as SC injections twice a week
Study NCT01547897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NOX-E36
Description: 0.5 mg/kg study drug or placebo as SC injections twice a week
Study NCT02027402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with drain insertion
Description: In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
Study NCT03958084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Straight Leg Raise
Description: The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.
Study NCT04457557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced concentration of local anesthetic (ropivacaine)
Description: Reduced concentration of ropivacaine We usually use 0.5% ropivacaine in our facility. The intervention group used 0.15% ropivacaine 15 ml
Study NCT04457557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual concentration of local anesthetic (ropivacaine)
Description: 0.5% ropivacaine 15ml
Study NCT01949779 — intervention group
Intervention type: DEVICE
Intervention: TransForm™ Occlusion Balloon Catheter
Description: TransForm™ Occlusion Balloon Catheter
Study NCT02154984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Follow tRD
Study NCT02154984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Receive coaching calls
Study NCT02154984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02813070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Flutemetamol
Description: PET brain imaging and Magnetic resonance brain imaging
Study NCT04179721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PES-4-BPSD Model
Description: Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks training the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training).
Study NCT04179721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The attention control condition
Description: Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks to train the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training).
Study NCT04099043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cascade Continuous Glucose Monitoring System
Description: Continuous Glucose Monitoring for 15 days
Study NCT01593202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Description: 16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively.
Study NCT01593202 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: 16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
Study NCT02036957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BALM ARM
Description: The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
Study NCT02036957 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO ARM
Description: The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
Study NCT02232308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nizatidine
Description: Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
Study NCT02232308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
Study NCT02232308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
Study NCT04295005 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: film coated tablet
Study NCT02404012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Description: Participants will be provided supplementation for 8 weeks
Study NCT02404012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral iron supplementation
Description: Participants will be provided supplementation for 8 weeks
Study NCT03199261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rE-4 Injection
Description: During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
Study NCT03199261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rE-4 Freeze-dried Powder
Description: During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
Study NCT04295005 — intervention group
Intervention type: DRUG
Intervention: DPP-4i
Description: film coated tablets, specifically Sitagliptin
Study NCT04295005 — intervention group
Intervention type: DRUG
Intervention: GLP-1-RA
Description: subcutaneous injection or tablet
Study NCT03826290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR-integrated diabetes dashboard
Description: The diabetes dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface.
Study NCT00692094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
Study NCT00692094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
Study NCT00692094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
Study NCT00692094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
Study NCT04152902 — intervention group
Intervention type: OTHER
Intervention: Objective outcome
Description: The final outcome of surgical therapy was assessed according to a semi-quantitative scale graded as excellent, good, fair and poor, according to quantitative grades for dysphagia, reflux symptoms and oesophagitis
Study NCT04152902 — intervention group
Intervention type: OTHER
Intervention: Quality of life
Description: SF-36 Questionnaire
Study NCT02142647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a high-protein complementary diet with meat
Description: infants will consume a high-protein complementary diet with protein mainly from meat
Study NCT02142647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a high-protein complementary diet with dairy
Description: infants will consume a high-protein complementary diet with protein mainly from dairy
Study NCT02052310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arm.
Study NCT02052310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.
Study NCT02773550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Low dose of bortezomib
Study NCT02773550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT02773550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT03217448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
Study NCT03217448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
Study NCT02219893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOC31PE Immunotoxin
Description: Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
Study NCT03866941 — intervention group
Intervention type: BEHAVIORAL
Intervention: causes of abuse synthetic cannibinoids
Description: Epidemiological data (age, sex, residence, occupation, route of abuse, the cause of abuse and smoking) (2) Symptoms and signs (seizures, psychosis, hallucinations) (3) Injuries and their relation to violence (type of wound, type of instrument, number of injuries, external or internal injuries and assailant or victim).
Study NCT02657616 — intervention group
Intervention type: DRUG
Intervention: vitamin-k-antagonists
Study NCT02657616 — intervention group
Intervention type: DRUG
Intervention: Novel oral anticoagulants
Study NCT04356833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1
Description: Patients in the cohort 1 rt-PA group will receive the first dose as soon as possible after registration. 10mg rt-PA in 5mL diluent will be administered by nebulisation every 6 hours for 14 days, resulting in a total daily dose of 40mg.